Executing Change in the Management of Chronic Kidney Disease

ASN 2002 Offical Evening Symposium, November, 2002
Access to this symposium is free, but you must first be a registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please register at this link and select a username and password.
Classification and Staging of CKD: Improving Multidisciplinary Care
Adeera Levin, MD
The Scope of CKD and Its Complications
William McClellan, MD
The Cutting Edge of Anemia Management in CKD
Ajay Singh, MD
The Effects of Anemia Correction on Renal and Cardiovascular Outcomes
Lawrence McMahon, MD

The educational objectives are:

1. Describe a proactive patient management approach to the treatment of patients with CKD, using the most recent diagnostic and treatment guidelines available to nephrology and other clinical disciplines.
2. Recognize and discuss the prevalence of CKD and its comorbidities, their clinical implications, and innovative screening programs for identifying CKD and its complications.
3. Summarize new strategies for the treatment of the anemia of CKD and the effects of anemia correction on both cardiac and renal function.
Adeera Levin, MD
St Paul's Hospital
University of British Columbia
Vancouver, Canada.

William McClellan, MD
Emory University School of Medicine
Atlanta, GA.

Ajay Singh, MD
Brigham and Women's Hospital
Boston, MA.

Lawrence McMahon, M.D.
Royal Melbourne and Western Hospitals
Melbourne, Victoria, Australia

This program is accredited for 1.5 CME credit hours by the American Society of Nephrology and for 1.5 CE Contact Hours for nurses by the Renal Education Association.

Date of Original Release: February 1, 2003
CME Credit Eligible Through: May 1, 2004
CME/CE Estimated Completion Time: 1.5 hours
Target Audiences: Nephrologists, internists, general practicioners, and nurses treating patients with CKD.
Method of participation: Listen to the talks, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the post-test answer feedback material, and complete the evaluation form. CME/CE certificates are provided on-line after completion.

Chronic kidney disease affects 30-40 million Americans, of whom several thousand require renal replacement therapy. These selected lectures are chosen by the HDCN editor and ASN Postgraduate Medical Director to reflect those areas of practice of greatest interest to the clinician, and areas where recent progress has occurred. The web extension of these ASN lectures will allow nephrologists and other physicians who were unable to attend the live sessions to gain similar benefit from these presentations.

The American Society of Nephrology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Renal Education Association is accredited by the State of California Board of Nursing to provide continuing education for nurses (provider number: CEP 13092).

The American Society of Nephrology designates this educational activity for category 1.5 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

This official ASN symposium was sponsored by a restricted educational grant from Ortho Biotech Products, LP.

American Society of Nephrology, the Renal Education Association, as well as HDCN have conflict of interest policies that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Dr. Levin: Has grants, research support, consultantships, board positions or honoraria from: Ortho Biotch Products, L.P., Amgen, Genzyme, Roche, and Merck
Dr. McClellan: is a clinical investigator for Ortho Biotech Products, L.P.
Dr. Singh: Has grants, research support, consultantships, board positions, or honoraria from: Ortho Biotech Products, L.P., CHOIR Study Principal Investigator, Pfizer, DCI Medical Director and Sherine Medical. He is also a scientific advisor for FlowMedica and Sherine Medical.
Dr. McMahon: Has grants, research support, or honoraria from: Janssen-Cilag, Ortho Biotech Products, L.P. and Amgen. He is also a scientific advisor for Janssen-Cilag and Ortho Biotech Products, L.P.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The American Society of Nephrology, the Renal Education Association, and HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

To complete this educational activity, the user will need Windows or Macintosh operating software, a connection to the internet with a 28.8 kbps MODEM or better. The computer should have an audio card with speakers. An audio player, either the Windows Media Player from Microsoft or the Real Player from Real Media (www.real.com) is required and either can be downloaded for free per instructions on the individual lecture pages. Acrobat Reader is required to print the CME or CE certificate, and this can be download free from www.adobe.com.

For any questions concerning this activity please send an email to or call HDCN at 630-325-3276.